吡咯替尼可改善既往接受过治疗的HER2阳性转移性乳腺癌患者的生存期。
Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer.
作者信息
Jacobson Anne
出版信息
Oncologist. 2022 Mar 28;27(Suppl 1):S5-S6. doi: 10.1093/oncolo/oyac013.
Abstract
In the phase III PHOEBE trial, treatment with pyrotinib plus capecitabine significantly improved overall survival compared with lapatinib plus capecitabine in patients with previously treated HER2-positive metastatic breast cancer.
摘要
在III期PHOEBE试验中，对于既往接受过治疗的HER2阳性转移性乳腺癌患者，与拉帕替尼加卡培他滨相比，吡咯替尼加卡培他滨治疗显著改善了总生存期。
相似文献
1
Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer.吡咯替尼可改善既往接受过治疗的HER2阳性转移性乳腺癌患者的生存期。
Oncologist. 2022 Mar 28;27(Suppl 1):S5-S6. doi: 10.1093/oncolo/oyac013.
2
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.吡咯替尼治疗转移性 HER2 阳性乳腺癌的真实世界数据：拉帕替尼治疗后患者和脑转移患者疗效可观。
Cancer Res Treat. 2020 Oct;52(4):1059-1066. doi: 10.4143/crt.2019.633. Epub 2020 Apr 24.
3
Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients.吡咯替尼治疗增强 HER2 阳性脑转移乳腺癌患者的放射敏感性。
Anticancer Drugs. 2022 Jan 1;33(1):e622-e627. doi: 10.1097/CAD.0000000000001199.
4
Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.吡咯替尼为基础的治疗方案在 HER2 阳性转移性乳腺癌患者中的有效性和安全性：一项真实世界的回顾性研究。
Cancer Med. 2021 Dec;10(23):8352-8364. doi: 10.1002/cam4.4335. Epub 2021 Oct 21.
5
[Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].吡咯替尼口服治疗HER2阳性转移性乳腺癌的疗效与安全性：真实世界实践
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Apr 18;52(2):254-260. doi: 10.19723/j.issn.1671-167X.2020.02.010.
6
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.吡咯替尼的 I 期研究和生物标志物分析，一种新型不可逆的泛-ErbB 受体酪氨酸激酶抑制剂，用于治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者。
J Clin Oncol. 2017 Sep 20;35(27):3105-3112. doi: 10.1200/JCO.2016.69.6179. Epub 2017 May 12.
7
Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.吡咯替尼联合卡铂治疗既往紫杉类、蒽环类和曲妥珠单抗治疗的 HER2 阳性复发转移性乳腺癌患者的持久临床获益。
Ann Palliat Med. 2020 Sep;9(5):3684-3689. doi: 10.21037/apm-20-1363.
8
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.吡咯替尼的发现与研发：一种新型不可逆表皮生长因子受体/人表皮生长因子受体 2 双酪氨酸激酶抑制剂，具有良好的安全性，可用于治疗乳腺癌。
Eur J Pharm Sci. 2017 Dec 15;110:51-61. doi: 10.1016/j.ejps.2017.01.021. Epub 2017 Jan 21.
9
Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2 Breast Cancer Cells to 5-Fluorouracil.吡咯替尼增敏 5-氟尿嘧啶耐药 HER2 阳性乳腺癌细胞对 5-氟尿嘧啶的敏感性。
Oncol Res. 2020 Dec 10;28(5):519-531. doi: 10.3727/096504020X15960154585410. Epub 2020 Jul 29.
10
Pyrotinib: First Global Approval.吡咯替尼：全球首次获批。
Drugs. 2018 Nov;78(16):1751-1755. doi: 10.1007/s40265-018-0997-0.
引用本文的文献
1
Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits.吡咯替尼治疗HER2阳性晚期乳腺癌脑转移患者的真实世界数据：单中心回顾性分析及分子特征
Front Oncol. 2023 Jun 16;13:1105474. doi: 10.3389/fonc.2023.1105474. eCollection 2023.
2
The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer.不可逆泛HER酪氨酸激酶抑制剂在HER2阳性转移性乳腺癌治疗中的作用。
Front Pharmacol. 2023 Mar 2;14:1142087. doi: 10.3389/fphar.2023.1142087. eCollection 2023.
3
Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective.用于治疗人表皮生长因子受体 2 阳性晚期乳腺癌的新型疗法：加拿大视角。
Curr Oncol. 2022 Apr 13;29(4):2720-2734. doi: 10.3390/curroncol29040222.
本文引用的文献
1
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌（PHOEBE）：一项多中心、开放标签、随机、对照、Ⅲ期临床试验。
Lancet Oncol. 2021 Mar;22(3):351-360. doi: 10.1016/S1470-2045(20)30702-6. Epub 2021 Feb 11.
Zotero 插件